On September 25, 2024 PDX Pharmaceuticals reported that it has received a $250,000 SBIR Commercialization Readiness Program (CRP) grant (SB1CA287735) from the National Cancer Institute (NCI) to advance ARAC-02, our next-gen immunotherapy for non-small cell lung cancer (NSCLC) (Press release, PDX Pharmaceuticals, SEP 23, 2024, View Source [SID1234646860]). This funding supports intellectual property (IP) protection of our core nanotechnology (Pdx-NP) and ARAC-02, as well as the initiation of a GMP-compliant manufacturing campaign. The goal is to enhance commercialization readiness and prepare for clinical trials. Huge congrats to our team, and a big thank you to the NCI for their continued support!

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!